Skip to content
Parakho

GlaxoSmithKline Pharmaceuticals Ltd

NSE GLAXOBSE 500660

Q1 FY27, unaudited

Revenue
₹924.42 Cr
Profit after tax
₹253.33 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations924.42+14.86%3,790.20
Other income61.63+40.84%142.56
Total income986.05+16.20%3,932.76
Employee benefit expense159.04+4.24%607.25
Finance costs0.97+130.95%2.73
Depreciation & amortisation15.84+2.06%66.44
Total expenses648.07+13.69%2,559.17
Profit before tax337.98+21.33%1,376.23
Tax expense84.65+14.59%364.41
Profit after tax253.33+23.76%1,011.82
Total comprehensive income253.33+23.76%1,004.28
Earnings per share
Earnings per share, basic₹14.95₹59.00
Earnings per share, diluted₹14.95₹59.00

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Earnings call

GlaxoSmithKline Pharmaceuticals Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 51 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 19 Aug 2026.